Endocrine Material Exam Two Flashcards
Metformin/Glumetza XR
Improved insulin sensitivity, lower hepatic production and GI absorption
Biguanide
CI: severe renal function eGFR <30
Warning: Lactic Acidosis, Somnolence, Malaise, Myalgia, & Respiratory Distress
DO NOT initiate if eGFR 30-45 mL/min
AE: Diarrhea
PC:
1. Take with food
2. Titrate dose
3. Use XR formulation
Dose: 1000-2550 mg
Titration Schedule for Metformin
Week 1: 500 mg QD
Week 2: 500 mg BID
Week 3: 500 mg AM, 1000 mg PM
Week 4: 1000 mg BID
SGLT2 Inhibitors
Decrease reabsorption of filtered glucose, increase excretion
Invokana, Farxiga, Jardiance, and Steglatro
CI: dialysis patients
Warning: volume depletion, bone fractures, lower limb amputation
AE: INCREASED urination and UTI infections
PC: keep genital area clean
Dosing: PO QD
You must consider an SGLT2 if the patient has PMH f HF, FM, or CKD
What are the dose adjustments for SGLT2 Inhibitors?
Invokana eGFR <30
Farxiga eGFR <45
Jardiance eGFR <30
Steglatro eGFR <45
These eGFR = not recommeneded to utilize SGLT2 specificites
Invokana eGFR 30-60 recommend dose ADJUSTMENT
What are the Landmark trials for Canagliflozin?
CANVAS = cardiovascular
CREDENCE = renal
Invokana
What are the Landmark trials for Empagliflozin?
EMPA-REG = cardiovascular
EMPEROR Reduced/Preserved = HF
Reduced = HFrEF Preserved =HFpEF Jardiance
What are the Landmark trials for Dapagliflozin?
DAPA-HF = HF
DAPA-CKD = renal
Farxiga
GLP-1 Receptor Agonist
Increase insulin secretion by beta cells
Decreasee glucagon, gastric emptying, and increased satiety
Byetta, Victoza, Adlyxin, Trulicity, Ozempic, and Mounjaro
CI: Medullary Thyroid Carcinoma
Warning: Pancreatitis
AE: Nausea/Diarrhea/HA
PC:
1. Nausea will likely subside over time
2. SUBQ
Byetta/Exenatide
GLP-1 Agonist
SQ BID
Starting Dose: 5 mcg
Max Dose: 10 mcg
CI: CrCl <30
PC: Administer within 60 minutes prior to AM/PM meal
Victoza/Liraglutide
GLP-1 Agonist
SQ QD
Starting Dose: 0.6 mcg
Max Dose: 1.8 mcg
Landmark Trial: LEADER
Adlyxin/Lixisenatide
GLP-1 Agonist
SQ QD
Starting Dose: 10 mcg x 14 days
Max Dose: 20 mcg on day 15
Trulicity/Dulaglutide
GLP-1 Agonist
SQ Once Weekly
Starting Dose: 0.75 mg
Max Dose: 4.5 mg
Landmark Trial: REWIND
Ozempic/Semaglutide
GLP-1 Agonist
SQ Once Weekly
Starting Dose: 0.25 mg
Max Dose: 2 mg
Landmark Trial: SUSTAIN 6
Mounjaro/Tirzepatide
GLP-1 Agonist
SQ Once Weekly
Starting Dose: 2.5 mg
Max Dose: 15 mg
What are the GLP 1 Receptor Agonists used for Weight Loss?
Saxenda/Liraglutide: SQ QD, titrate weekly to target dose 3g QD
Wegovy/Semaglutide: SQ once weekly, titrate q4 wks to maintenance dose of 2.4 mg once weekly
DDP-4 Inhibitors
Januvia, Onglyza, Tradjenta, and Nesina
Warning: pancreatitis, renal impairment
AE: HA
Dosing: PO QD
What are the dose adjustments for DDP-4 Inhibitors?
Januvia eGFR <45
Onglyza eGFR <45 or Strong CYP 3A4 Inhibitors
Tradjenta NONE
Nesina eGFR <60
Insulin Secretagogues
Sulfonylurea: Amaryl, Glucotrol, Diabeta
Meglitinides: Prandin and Starlix
CI: T1DM, sulfa allergy
Warning: HYPOglycemia, renal/hepatic dysfunction
DDI: BB = mask s/s of hypoglycemia
AE: weight gain
PC: when to administer in relation to meals
Amaryl/Glimepiride
PO QD with Breakfast
Titrate Q1-2 wks; intermediate acting
Consider lower dose and slow titration w/ eGFR <60
Glucotrol/Glipizide
PO QD/BID
Take 30 minutes pre-meal; titrate Q1-2 wks
Start lower dose and slow titration with eGFR <50
Diabeta or Micronase/Glyburide
PO QD with Breakfast
Titrate Q1-2 wks
NOT recommended with eGFR <60
Prandin/Repaglinide
TID with meals
Take 30 minutes pre-meal; titrate weekly
Start lower dose and slow titration with eGFR <40
Starlix/Nateglinide
TID with meals
Take 30 minutes pre-meal; titrate weekly
Start lower dose with eGFR <30
Thiazolidinediones
Actos and Avandia
CI: T1DM, Patients with Class III or IV HF
Warning: hepatic dysfunction
AE: Edema, Weight Gain
PC: S/S of fluid retention
Dosing: QD
Titrate Q3 months